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INTRODUCTION 
The apolipoprotein E (APOE)-e4 allele is neither necessary nor sufficient 
to cause Alzheimer's disease (AD) because it develops in the absence of 
APOE e4,1v2 and some persons escape the disease despite having an APOE 
€4 allele.3 Although the presence of the €4 allele of the APOE gene has been 
consistently associated with an increased risk of it is apparent that 
the degree of risk may be modified by age,'OVz1 ethnic group? certain 
risk  factor^?^ and possibly other genes.% 
Roses et al.11*21 proposed that APOE genotypes have a direct influence 
on the age at onset of disease. In both familial and sporadic AD, an earlier 
age at onset among APOE €4 homozygous and APOE €4 heterozygous cases 
than among those cases with other APOE genotypes. Thus, it is possible that 
hAddress for correspondence: Richard Mayeux, G.  H. Sergievsky Center, 630 West 168th Street, 
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APOE genotypes strongly influence age at onset and that certain factors, 
both genetic and nongenetic, modify this effect by shifting the distribution 
curves. 
In this review we will discuss demographic and putative risk factors that 
may modify (enhance or diminish) the association between APOE genotypes 
and AD. 
METHODS 
Subjects and Setting 
All information was obtained from AD cases and controls rgsiding in the 
same community and have been described in several earlier pubh~at ions.~.’ .~~.~~ 
Two different ascertainment methods were used to identify the study popula- 
tions. Cases and controls were identified as part of a comprehensive commu- 
nity-based registry of all dementias in northern Manhattan and a random 
sample of Medicare recipients as previously described.*-’ The Columbia Uni- 
versity institutional review board reviewed and approved this project. All 
individuals provided written informed consent. Both groups of cases and 
controls were followed over a four-year period. 
Diagnosis of Alzheimer’s Disease 
The diagnosis of AD was based on standard research  riter ria.^^.^' We 
previously reported the devglopment of our diagnostic method and its relation- 
ship to the cultural and educational demographics of this ~ommunity.~~.’~ The 
reliability and consistency of these assessments have also been described.30 
Age at Onset 
Because we used a cross-sectional design with follow-up, a large number 
of cases identified with prevalent AD were included. We did not attempt to 
use an estimate of the age at onset because of the difficulty in substantiating 
this type of information. To improve validity, we used a more conservative 
method and censored the age at onset (left ~enso red ) .~ ’ -~~  We have recently 
described the method of estimate,relativing risks using this type of appr~ach.’~ 
Ethnic Group 
Ethnic group was classified by self-report using the format of the 1990 
United States Census Bureau.34 This allows each person to identify him or 
herself as belonging to particular racial or ethnic group. Each person is 
then asked whether or not he or she is of “Hispanic” origin. 
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APOE Genotyping 
Genomic DNA was amplified by polymerase chain reaction (PCR) and 
subjected to Cfol restriction analysis using APOE primers and conditions 
modified from those as previously described by Hixson and Vernier.35 Geno- 
types were determined without knowledge of patient or control status. 
Risk Factors and Family History 
A structured interview was used to inquire about behaviors such as smok- 
ing, alcohol use, coffee consumption, dietary habits, antiperspirant use, insec- 
ticide exposure, exposure to household solvents, head injury, athletic activity 
now and in the past, previous hip or wrist fractures, and use of exogenous 
hormones. For several of the items, we attempted to determine the “dose” 
of the exposure with follow-up questions. A family history interview for AD 
and other neurological disorders in first-degree relatives (parents and full 
siblings) was obtained. The interviews were given in English or Spanish 
according to the preference of the patient’s informant or the control. The 
reliability of this interview has been reported.36 
Data Analysis 
APOE allele frequencies were determined by counting alleles and calculat- 
ing sample proportions. To compare across ethnic groups, APOE allele fre- 
quencies were calculated using all data from all controls and a 10% random 
sample of the total number of cases within each ethnic group to create a 
representative population. For comparison of cases and controls within and 
across ethnic groups, APOE allele frequencies were calculated for all subjects. 
We used an iterative method to obtain the nonparametric maximum likeli- 
hood estimate of age at onset from the “self-consistent equati~n,’’~.~’ and 
then used a parametric approach to develop a proportional hazards regression 
model to estimate the relative risks of AD by APOE genotype?’ 
Univariate and multivariate relative risks for AD associated with various 
APOE genotypes were derived from the proportional hazards model and both 
univariate, and multivariate odds ratios for AD associated with APOE €4 
were also calculated from logistic regressi0n,2~ adjusting for age, education, 
and ethnic group. 
RESULTS 
Demographics 
Data were available for 276 cases and 405 healthy elderly unrelated 
controls. Cases and controls differed by gender (75% AD women vs. 66% 
control women, x2 = 6.5, p < 0.01). In all ethnic groups combined, cases 
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TABLE I. Demographics and APOE Allele Frequency among Patients with 
Alzheimer's Disease and Controls by Ethnic Groups 
~ ~~~ ~~ ~ ~~~ 
Ethnic Groups n Age Education APOE-€3 APOE-E~ APOE-E~ 
African-American 
AD 106 78 (7.6) 7.4 (4.0) 0.66 0.23 0.1 1 
Controls 154 74 (5.8)" 9.4(3.8)" 0.73 0.20 0.07 
AD 59 71 (9.1) 13.4 (4.2) 0.70 0.27 0.03 
Controls 112 72 (8 .5)  12.3(4.0)" 0.84 0.09 0.07 
AD 140 77 (8.3) 4.8 (3.7) 0.74 0.19 0.07 
Controls 219 73 (6.1)" 7.0(4.3)" 0.83 0.10 0.07 
NOTE: Allelic frequencies differed significantly between cases and controls within and across 
Caucasian 
Hispanic 
ethnic groups. See text for explanation. 
Denotes significant difference within each stratum (p c 0.05). 
were older (AD 76.4 2 standard deviation [SD] 9.2 [range 46 to 961) than 
controls (72.9 ? SD 6.7 [range 46 to 931, p c 0.05). African-Americans and 
Hispanics were older and less well educated than Caucasians (TABLE I ) .  
Cases also had less education (AD 7.4 ? 5.0 vs. controls 8.8 ? 4.5, p c 
0.05) than controls. 
APOE Allele Frequencies 
The APOE allele frequencies also differed significantly in the three ethnic 
groups (x2 = 24.6, 4df, p c 0.0001). The frequency of APOE €4 among 
African-Americans was higher with increasing age. Among African-Ameri- 
cans in the lowest quartile of age (below age 68) to the highest (age 77 
and older) the APOE €4 frequency was greater than 20%, whereas among 
Caucasians the frequency decreased from 16% to 7.5%. APOE allele frequen- 
cies did not differ by gender. 
Among AD cases, the distribution of APOE alleles also differed across 
ethnic groups (x2 = 15.1, df4, p = O.Ol), with higher frequencies of APOE 
€4 in Caucasians (29%) than in African-Americans (24.7%) or Hispanics 
(1 8.6%) and with higher frequencies of APOE €2 in African-Americans 
( 1  2.1 %) than in the other two ethnic groups (Caucasians 2.7%, Hispanics 
6.6%; see TABLE 1). 
Relative Risk 
Specific APOE genotypes in cases and controls for each ethnic group 
are found in TABLE 2. The relative risk (RR) of AD among African-Americans 
homozygous for the APOE €4 allele was significantly increased (RR = 3.3; 
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TABLE 2. Relative Risk of Alzheimer’s Disease by APOE Genotypes in 
Cases and Controls by Ethnic Group 













49 19 28 10 
126 36 86 12 
1.0 1.4; (0.8-2.6)” 0.6; (0.4-0.9)” 3.3; (1.6-6.8)” 
30 1 24 4 
108 15 44 4 
1.0 0.3; (0.4-2.3)” 3.2; (1.8-5.8)” 5.3; (1.6-16.1)” 
80 13 38 6 
228 43 79 9 
1.0 0.9; (0.5-1.8)” 1.5; (1.0-2.2)“ 2.5: (1.1-5.8Y 
NOTE: The number in each column represents the number of individuals with that specific 
a 95% ci. 
genotype. 
95% c.i. 1.6-6.8) compared with APOE ~ 3 k 3  genotypes. The risk associated 
with APOE €4 heterozygosity was significantly decreased (RR = 0.6; 95% 
c.i. 0.4-0.9). For Caucasians, the relative risks associated with either APOE 
€4 homozygosity (RR = 5.3; 95% c.i. 1.6-16.1) or heterozygosity (RR = 3.2; 
95% c.i. 1.8-5.8) were significantly increased compared with APOE ~ 3 k 3  
genotypes. Among Hispanics, the relative risks were increased for APOE €4 
homozygous individuals (RR = 2.5; 95% c.i. 1.1-5.8) and in APOE €4 
heterozygous individuals (RR = 1.5 95% c.i. 1 .O-2.2) compared with APOE 
€31~3 genotypes. Each analysis was repeated stratifying by gender and by 
including educational level as a covariate, but the results were identical. 
We also examined the protective effect of APOE genotypes with one or 
more €2 alleles using APOE €31~3 genotypes again as the reference. The 
risk of disease associated with APOE €2 was lower among Caucasians (RR = 
0.3; 95% c.i. 0.4-2.3), but not AErican-Americans (RR = 1.4; 95% c.i. 0.8- 
2.6) or Hispanics (RR = 0.9; 95% c.i. 0.5-1.8). 
Head Injury 
In a subset of 113 patients with AD and 123 healthy elderly persons we 
used a case-control design to examine the joint effects of head injury and 
APOE genotypes. Thirteen patients (1 1.5%) with AD had a history of head 
trauma associated with loss of consciousness preceding onset of dementia, 
while 10 (8.1%) controls reported a similar injury. The odds ratio (OR) for 
AD associated with head injury was 1.5 (95% c.i. 0.5-3.5, p = 0.5). Using 
persons with neither a history of head injury nor an APOE €4 allele as the 
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reference group, we estimated the OR for AD associated with both a history 
of traumatic head injury and the presence of at least one APOE €4 allele 
(OR = 10.5; 95% c.i. 1.3-87.8), traumatic head injury alone (OR = 1.0; 95% 
c.i. 0.3-2.9), and the presence of APOE €4 alone (OR = 2.0; 95% c.i. 1.1- 
3.5) adjusting for age by logistic regression. The OR for the joint effect of 
head injury and APOE €4 exceeded that expected from the independent 
effects of both risk factors, suggesting a synergistic relationship. 
DISCUSSION 
We examined the effect of APOE genotypes on the relative risk of AD 
among three distinct ethnic groups residing in New York City. The APOE 
~ 4 k 4  genotype was associated with a higher relative risk of AD in all ethnic 
groups. Among Caucasians and Hispanics, APOE €4 heterozygosity was also 
associated with a significantly higher relative risk of AD compared with 
APOE genotypes without an €4 allele. Among African-Americans, however, 
the increased risk was restricted to persons with the APOE ~ 4 k 4  genotype; 
APOE €4 heterozygotes had a significantly lower relative risk of AD. Stratifi- 
cation by gender, family history of AD, or educational level did not change 
the association between APOE €4 and AD in any ethnic group. There was 
only minimal evidence of a reduced risk for AD associated with APOE €2 
genotypes in Caucasians, and there was no decrease in risk for African- 
Americans or Hispanics. 
A strong association between APOE €4 and AD has been previously 
reported among African-Americans in Indiana.” The APOE €4 frequency 
among controls (0.12) was lower than that reported here. Differences in 
APOE allele frequencies by ethnic group are well established,3742 and there 
are regional differences among African populations.4w2 
The APOE €4 allele frequency among the African-Americans in this 
study did not decline with age in contrast to the trend noted among Caucasians 
in the United States and E ~ r o p e . 4 ~ ~  The decline in the frequency of APOE 
€4 with age in Caucasians has been attributed to mortality from heart dis- 
e a s e , @ ~ ~ ~ ~  because variations in the APOE locus affect cholesterol concentra- 
t i o n ~ . ~ ’ . ~ ~  APOE €4 does not consistently predict cholesterol concentrations 
in persons of African  rigi in.^.^'.^^ Thus it is possible that the APOE protein 
may be modified by other factors in African-Americans. 
The data concerning head injury in this population suggest a synergistic 
relationship between an environmental risk factor and APOE €4. In the 
absence of APOE €4, the risk of AD associated with head injury was not 
elevated; thus, our results indicate that the effect of head injury on AD risk 
may be restricted to persons either homozygous or heterozygous for APOE 
€4. The findings are most consistent with a model in which an environmental 
risk factor has no effect alone, yet it exacerbates the effect of genetic suscepti- 
bility. The findings further integrate the roles of P-amyloid and APOE €4, 
suggesting that the APOE €4 gene increases susceptibility to AD, which can 
be exacerbated by the effects of an environmental stimulus such as traumatic 
head injury. 
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Population-based prospective studies that address the demographic factors 
of age, ethnic group, gender, and socio-economic status should provide infor- 
mation concerning the risk of AD associated with APOE €4 in these circum- 
stances. Similarly, previous investigations of risk factors should be repeated 
to include APOE genotypes in order to appreciate the relationship between 
genetic and environmental factors in this disease. 
SUMMARY 
The association between apolipoprotein E (APOE)+4 and Alzheimer’s 
disease has been confirmed worldwide. We and others have observed a 
diminished association in the very old and among African-Americans com- 
pared to Caucasians and Hispanics in New York. In this review we describe 
a new method we developed to compare relative risks by APOE genotypes 
in an expanded cohort of cases and controls from three ethnic groups in a 
New York City community and discuss the association as between APOE €4 and Alzheimer’s disease as modified by head injury. 
Compared to persons with APOE ~ 3 k 3  genotypes, relative risk (RR) for 
Alzheimer’s disease associated with APOE €4 homozygosity was similar 
across ethnic groups (African-American RR= 3.3; 95% c.i. 1.6-6.8; Caucasian 
RR = 5.3; 1.6-16.0; Hispanic RR = 2.5; 1.1-5.8). The risk was also increased 
for APOE €4 heterozygous Caucasians (RR = 3.2; 1.8-5.8) and Hispanics 
(RR 1.5; 1.0-2.2) but not African-Americans (RR = 0.6; 0.4-0.9). Risk of 
AD was not significantly diminished for individuals in any group with APOE 
~ 2 / ~ 2  or - ~ 2 / ~ 3  genotypes. A 10-fold increase in the risk of Alzheimer’s 
disease was associated with both APOE €4 and a history of traumatic head 
injury, compared to a twofold increase in risk with APOE €4 alone. Head 
injury in the absence of an APOE €4 allele did not increase risk. 
These results imply that in Alzheimer’s disease genotypic risk associated 
with APOE may be influenced by age, ethnicity, and certain enviromental 
factors. 
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